CRYO Stock Overview
American CryoStem Corporation develops, markets, and licenses adipose tissue derived technologies for use in the fields of Regenerative and Personalized Medicine. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
American CryoStem Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0001 |
| 52 Week High | US$0.15 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 11 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -99.91% |
| 33 Year Change | -99.98% |
| 5 Year Change | -99.98% |
| Change since IPO | -99.99% |
Recent News & Updates
Recent updates
Shareholder Returns
| CRYO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 2.4% | 0.5% |
| 1Y | -99.9% | 15.6% | 30.7% |
Return vs Industry: CRYO underperformed the US Biotechs industry which returned 3% over the past year.
Return vs Market: CRYO underperformed the US Market which returned 25% over the past year.
Price Volatility
| CRYO volatility | |
|---|---|
| CRYO Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CRYO's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine CRYO's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | n/a | John Arnone | www.americancryostem.com |
American CryoStem Corporation develops, markets, and licenses adipose tissue derived technologies for use in the fields of Regenerative and Personalized Medicine. The company’s products include CELLECT collection, transportation, and storage system, which is a solution for physicians to collect and deliver tissue samples; ATGRAFT adipose tissue storage service, a fat collection, processing, and storage solution that enables physicians to provide their patients with tissue products and cell storage options; and ATCELL adipose derived stem cells. It also offers ACSelerat cell culture media products for growing human stromal cells.
American CryoStem Corporation Fundamentals Summary
| CRYO fundamental statistics | |
|---|---|
| Market cap | US$4.96k |
| Earnings (TTM) | -US$3.81m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs CRYO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CRYO income statement (TTM) | |
|---|---|
| Revenue | -US$227.03k |
| Cost of Revenue | US$31.56k |
| Gross Profit | -US$258.58k |
| Other Expenses | US$3.55m |
| Earnings | -US$3.81m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did CRYO perform over the long term?
See historical performance and comparison